Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

EyePoint Pharmaceuticals

NASDAQ: EYPT ↗$0.36 USD~$0.5B MCAP

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company developing sustained-release therapeutics for serious eye disorders, including age-related macular degeneration (AMD) and diabetic macular edema. Its lead program, DURAVYU, is an intravitreal implant delivering a tyrosine kinase inhibitor for sustained VEGF suppression.

Company Info

Sector:Ophthalmology / Biopharmaceuticals
Headquarters:Watertown, Massachusetts, USA
Founded:2005

Workforce & Restructuring Tracker

View Industry Layoff Tracker →
2026-10-19•Clinical Trial Setback•Watertown & Northbridge, MA, USA
105 roles (53%)Confirmed

Following a second pivotal Phase 3 primary-endpoint miss for DURAVYU (intravitreal vorolanib insert) in wet age-related macular degeneration (wet AMD), EyePoint terminated its late-stage wet AMD trials early, filed Massachusetts WARN notices to cut 105 positions (~53% of staff) across its Watertown and Northbridge facilities, and shifted clinical capital toward diabetic macular edema (DME).

Recent News

Leadership Team

Careers & Job Openings

See all open roles

Various
USA
Apply Now →